CoRegen, Inc. Receives FDA Clearance to Advance CRG-150 into Phase 1/2a Clinical Trials, Pioneering a New Frontier in Cell Therapy for Multiple Solid Tumor Types

CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients living with some of the most aggressive forms of cancer, today announced the U.S. Food and Drug Administration (FDA) ...
SWI swissinfo.ch

Stock Losses Extend on Chip Selloff, Oil Climbs: Markets Wrap

Asian equities fell as renewed selling in technology stocks deepened concerns that the AI-driven rally may have run ahead of ...
Technology Networks

HIV Vaccine Guides Immune Cells To Produce Neutralizing Antibodies

An experimental HIV vaccine trained immune cells to generate broadly neutralizing HIV antibodies in primates. The findings ...